Mark A. DeWitt

TL;DR: By rationally designing single-stranded DNA donors of the optimal length complementary to the strand that is released first, this work increases the rate of HDR in human cells when using Cas9 or nickase variants to up to 60%.

TL;DR: It is demonstrated that a delivery vehicle composed of gold nanoparticles conjugated to DNA and complexed with cationic endosomal disruptive polymers can deliver Cas9 ribonucleoprotein and donor DNA into a wide variety of cell types and efficiently correct the DNA mutation that causes Duchenne muscular dystrophy in mice via local injection, with minimal off-target DNA damage.

TL;DR: It is demonstrated that an accessible approach combining Cas9 RNP with an ssODN can mediate efficient HSPC genome editing, enables investigator-led exploration of gene editing reagents in primary hematopoietic stem cells, and suggests a path toward the development of new gene editing treatments for SCD and other hematopolietic diseases.

TL;DR: The data suggest that the two heads do not cooperate during movement, which suggests a fundamentally different mechanism of motility from that observed for other microtubule-based motors.

TL;DR: It is demonstrated that the gRNAs of Cas9 and Cpf1, and donor DNA can be chemically modified at their terminal positions without losing activity, and it is shown that 5’ fluorescently labeled donorDNA can be used as a marker to enrich HDR edited cells by a factor of two through cell sorting.